RxDoctor Payments Data

Elizabeth Pensler, DO

Surgery · Ferndale, MINPI 1659577963

Payments from drug & device makers

$33,912in general payments, 2019–2025

Across 163 payments — averaging $208.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$26K
  • Endologix LLC$3K
  • Boston Scientific$2K
  • Bard Peripheral Vascular, Inc.$919
  • Philips North America LLC$697
  • Medtronic$549
  • plus $1K from 17 others
$3,600in research payments, 2019–2025

Across 1 payment — averaging $3600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Skye Orthobiologics LLC$4K

What the payments were for

  • Food & beverage$8,41225%
  • Other$25,50075%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,912 in reported general payments places this provider in the 90th percentile of 1,081 surgery providers in Michigan.

See all surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$2,156,425
Medicare patients
213
Services billed
3,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban102$81,555
EliquisApixaban11$12,031
ClopidogrelClopidogrel Bisulfate383$3,629
Econazole Nitrate42$838
Ibuprofen144$694
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen98$620
Ammonium Lactate42$613
Celecoxib14$488
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$309
Triamcinolone Acetonide53$278
Naproxen13$89
Methylprednisolone13$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$42$81,555102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,081 surgery providers in Michigan.

Other surgery in Ferndale

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →